×

公司新闻

NEWS ▎康龙化成宣布控股联斯达
作者:LINKSTART  |   发布时间:2018-12-17 15:23  |   浏览次数:0  |  

Pharmaron Acquires Majority Ownership in LinkStart

Expands Pharmaron’s integrated offerings to clinical development in China

 

康龙化成宣布控股联斯达

旨在进一步布局中国临床开发一体化服务能力

 

Beijing, China, July 3rd, 2020 - Pharmaron, a fully integrated contract research and manufacturing organization offering end-to-end R&D services for the life science industry, announced today that it completed a follow-on investment to acquire the majority ownership in Beijing LinkStart SMO Ltd.(Linkstart), a third party clinical site management services organization (“SMO”) headquartered in Beijing, China. With the completion of this transaction, LinkStart becomes a subsidiary of Pharmaron.

 

中国,北京, 2020年7月3日

康龙化成宣布完成控股北京联斯达医药科技发展有限公司(提供第三方独立临床研究现场管理服务SMO,总部位于北京,英文名:LinkStart SMO Ltd.,以下简称联斯达)的交易,联斯达成为康龙化成的子公司。

 

This investment follows the path of Pharmaron’s previous strategic investment made in LinkStart in 2019, reflecting its continued confidence in LinkStart and strong commitment to clinical development service. This transaction will facilitate the implementation of Pharmaron’s clinical service strategy in China and in the world.

 

作为2019年战略性投资联斯达之后的追加投资,此次交易体现了康龙化成对联斯达的信心,彰显公司对拓展临床开发服务领域的决心,此举将促进公司在中国及全球临床服务能力建设。

 

Mr. Larry Lou, President and COO of Pharmaron commented, “We are delighted to have LinkStart join the Pharmaron family. Through this investment, together with our clinical CRO subsidiary CR Medicon, we will be able to further strengthen our clinical service capability and capacity in China. It is one step closer to realize Pharmaron’s strategy to integrate its global clinical platforms in China, the US and the UK, all together, creating additional, synergistic value for domestic and international partners. It will help create an end-to-end service platform ranging from discovery through preclinical to clinical development and manufacturing.”

 

康龙化成总裁兼COO楼小强先生表示:“欢迎联斯达加入康龙化成大家庭!结合之前对南京希麦迪的收购,我们在中国的临床开发服务能力得到进一步强化。康龙化成致力于战略性构建临床开发服务一体化平台,整合中、英、美三地优势,发挥协同效应,为国内外合作伙伴创造价值。”

 

Mr. Yang Liu, founder, CEO of LinkStart, expressed his enthusiasm about this transaction, “We are excited to join the Pharmaron group, a highly experienced global player in the life science service industry. With the strong support from Pharmaron since the strategic investment last year, the SMO service capability and business in LinkStart has grown rapidly. By further deepening our relationship, we are in a better position to serve our partners and to build a premier SMO brand in the life science industry.”

 

联斯达创始人、CEO刘洋先生对此次交易表示期待:“康龙化成在国际生命科学研发服务领域备具丰富的经验,我们很高兴加入这样的大家庭。联斯达自去年接受康龙化成战略投资后,获得了康龙化成强有力的支持,公司在SMO业务能力和业务体量均快速增长。此次进一步强化彼此伙伴关系,有利于我们更全面地融入康龙化成新药研究和开发服务大平台,为客户提供更优质的服务,打造行业领先的SMO品牌。我们对此充满信心。”  

 

About Pharmaron

 

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a leading fully-integrated pharmaceutical R&D service platform supporting the life science industry.   Founded in 2004, Pharmaron has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle.   With operations in China, US and UK staffed by over 8,000 employees, Pharmaron has excellent track record in delivering R&D solutions to its partners in North America, Europe, Japan and China. 

For more information: www.pharmaron.com

 

 

About LinkStart

 

LinkStart is a leading clinical SMO in China. Founded in 2012, headquartered in Beijing. LinkStart collaborates with over 500 hospitals in more than 110 cities in China, and is a preferred SMO service provider for100+ clinical research centers. LinkStart has conducted 900+ studies, of which 85% are the 1st class of new drugs and biological products, encompassing a broad spectrum of therapeutic areas.